WHO WE ARE.
SAPPIENS is a subsidiary of CXS Therapeutics, our bioinformatics platform dedicated to the identification and development of therapeutic molecules for diseases affecting the central nervous system.
SAPPIENS was created following the identification of a new drug candidate for Parkinson's disease, and aims to carry out the pharmaceutical development of a first therapeutic treatment, CXS003.
THE NEED FOR NEUROPROTECTIVE TREATMENT FOR PARKINSON'S DISEASE
10 million people worldwide suffer from Parkinson's disease. It represents a considerable socio-economical cost, a rising incidence and a doubling of prevalence over 25 years and a real burden for caregivers and patients alike.
THE FUNCTION OF CURRENT TREATMENTS
Symptomatic treatments to counteract the neurons' deficient production of dopamine. Duration of action decreases as the disease progresses.
THE OBJECTIVE OF NEUROPROTECTIVE TREATMENT
Preserve or even restore the functionality of neurons that are still viable, to compensate for the reduced response to symptomatic treatments and slow down the progression to loss of autonomy.
As the WHO points out, "worldwide, disability and mortality attributable to Parkinson's disease are increasing rapidly".
SAPPIENS AND ITS FIRST CANDIDATE FOR THERAPEUTIC USE : CXS003
A patent, an innovative and de-risked solution, a phase 2 in 2026.
A patent published in 2024 covering CXS003 and its novel combination of molecules.
An innovative treatment associated with improved survival of dopaminergic neurons in vitro/in vivo .
Initiation of our phase 2 development of CXS003 is actually scheduled for 2026.
CXS003 restores
neuronal viability
The use of CXS003 restores neurite neurite length and cell viability in an induced model of diseased neurons.
Healthy neurons
Diseased neurons
Diseased neurons + CXS003
The use of a innovative dosage greatly optimizes treatment effect.
*BDNF: brain-derived neurotrophic factor
CXS003 improves survival of dopaminergic neurons neurons in vivo.
CXS003 appears to improve the survival of dopaminergic neurons in the substantia nigra of a drastic model of neuronal intoxication.
This effect is associated with improvement
in behavioral phenotype
.
Within individuals, CXS003 improves parameters'initiating steps (and) andadjusting steps (correction).
CXS003, an innovative first program now ready to enter phase 2
A NETWORK OF EXCELLENCE
SUPPORTS OUR PROGRAM
Pre-clinical and clinical experts specialized in neurology and Parkinson's disease.
Hospital centers integrating a multidisciplinary research network throughout France.
National and international foundations in the fight against Parkinson's disease.
OUR TEAM
Clinical and scientific expertise. Key partners recognized for their skills. A complementary team made up of passionate members.
GABRIELLE GACHE
General Manager
Co-founder and board member
C-level Executive from the Pharma-Biotech industry, Advisor and Board Member with 25+ years experience in Corporate and Business Dev., Licensing and Access. President of " Swiss Healthcare Licensing Group "from 2015 to 2022.
GUILLAUME BRACHET
Scientific management
Co-founder and board member
Pharmacist - researcher. Expert in pharmaceutical innovation and biomedicines. Diagnosed with Parkinson's disease in 2018.
NADINE MACKENZIE
Medical management
Co-founder and board member
Rheumatologist. Medical Director in the pharmaceutical industry for 20+ years. Former member of the Executive Committee of LEO Pharma France.
ANTHONY ALIOUI
Scientific management
Co-founder and board member
PhD in genetics and molecular physiology. Expert in prevention and health promotion. Founder of the "MS PEDAGO" training organization.
GREGORY ARBIA
Finance Department
Board member
Doctorate in applied mathematics. Expert in business development and financing of research companies. Co-founder of " CHOICE Consulting " (company financing).
DJAMCHID DALILI
Strategy
Co-founder and board member
Ecole Polytechnique and PhD in nuclear physics. Founder of the 3W Academy (developer school). Founder and CEO of MedTech "DiamPark" (Parkinson's).
A scientific board of experts supports us in the design of our early development plan.
DAVID
DEVOS
Neurologist, Research Fellow at Lille University Hospital, NS-PARK Executive Committee
SIMON
STOTT
Doctor in neurobiology and director of research at the " Parkinson's Cure "
MARIE
FUZZATI
Doctor in biology and scientific director of " France Parkinson "
ANNIE-SOPHIE
ROLLAND
Doctor in neuroscience and researcher at Lille University Hospital (LiLNCog center)
ACKNOWLEDGED PARTNERS
INTERESTED IN INVESTING ?
Go to the "Valeureux" portal.
All key figures (current sales, forecasts, margins, etc.) and much more can be accessed via the dedicated area.
